A multi-centre double-blind parallel-group randomised controlled study to investigate efficacy safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared to donepezil and placebo in patients with cognitive impairment due to Alzheimer's Disease
M
Martin Farlow, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Not Recruiting
55 years - 100 years
All
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to test the safety and effectiveness of 4 different doses of the study drug BI 409306 compared to donepezil and placebo, and to measure changes in memory and thinking skills.
Detailed description of study
The purpose of this study is to test the safety and effectiveness of 4 different doses of the study drug BI 409306 compared to donepezil and placebo and measure changes in memory and thinking skills.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Alzheimer's disease
-
Age: 55 years - 100 years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 1504462375
